RecruitingNCT04001582

The United Kingdom Facioscapulohumeral Muscular Dystrophy Patient Registry

The UK Facioscapulohumeral Muscular Dystrophy Patient Registry


Sponsor

Newcastle University

Enrollment

1,018 participants

Start Date

May 1, 2013

Study Type

OBSERVATIONAL

Summary

Facioscapulohumeral Dystrophy (FSHD) is the third most common form of neuromuscular dystrophy worldwide with an estimated prevalence of one in 20,000. FSHD is an autosomal dominant genetic disease and is estimated to affect up to 3,000 people in the UK. The patient registry facilitates a questionnaire based research study to better characterise and understand the disease in the UK, and helps to identify potential participants eligible for clinical trials.


Eligibility

Inclusion Criteria1

  • \- All patients with a confirmed FSHD diagnosis (or pending diagnosis) who reside in the UK are eligible for inclusion.

Exclusion Criteria2

  • Any confirmed NMD other than FSHD
  • Living outside of the UK

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERPatient Registry

Participants who have volunteered to participate will complete various questionnaires relating to their condition.


Locations(1)

John Walton Muscular Dystrophy Research Centre

Newcastle upon Tyne, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04001582